Medtronic plc (MDT)
| Market Cap | 117.19B -1.7% |
| Revenue (ttm) | 37.54B +9.8% |
| Net Income | 5.23B +12.3% |
| EPS | 4.06 +12.1% |
| Shares Out | 1.28B |
| PE Ratio | 22.57 |
| Forward PE | 15.25 |
| Dividend | $2.88 (3.14%) |
| Ex-Dividend Date | Sep 25, 2026 |
| Volume | 5,119,406 |
| Open | 92.00 |
| Previous Close | 91.89 |
| Day's Range | 90.58 - 92.54 |
| 52-Week Range | 73.31 - 106.33 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 104.76 (+14.34%) |
| Earnings Date | Sep 1, 2026 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $104.76, which is an increase of 14.34% from the latest price.
News
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Medtronic Transcript: Wells Fargo 21st Annual Healthcare Conference
MedTech innovation is accelerating, driven by AI, robotics, and new therapies that expand patient access and improve outcomes. Strong Q1 growth is supported by high-performing franchises and investments, with Cardiac Ablation, hypertension, and surgical robotics as key drivers. The company will detail new opportunities at its upcoming Investor Day.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Medtronic executives to speak at upcoming investor conferences
GALWAY, Ireland, Sept. 4, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2026 Wells...
Dividend Aristocrat Stocks PEP and MDT Attract 10%+ Upside Targets Ahead of Key September Dates
Analysts see at least 10% upside in dividend aristocrat stocks PepsiCo ($PEP) and Medtronic ($MDT). This matters as the companies have ex-dividend dates of Friday, September 4, 2026, and Friday,…
Medtronic price target raised to $92 from $78 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Medtronic (MDT) to $92 from $78 and keeps a Hold rating on the shares.
Medtronic price target raised to $110 from $100 at UBS
UBS raised the firm’s price target on Medtronic (MDT) to $110 from $100 and keeps a Buy rating on the shares.
Medtronic price target raised to $115 from $100 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Medtronic (MDT) to $115 from $100 and keeps an Outperform rating on the shares. Cardiovascular products continue to drive Medtronic’s…
Medtronic price target raised to $99 from $86 at Truist
Truist raised the firm’s price target on Medtronic (MDT) to $99 from $86 and keeps a Hold rating on the shares. The company reported a solid Q1 revenue beat and…
Medtronic price target raised to $104 from $102 at Wells Fargo
Wells Fargo raised the firm’s price target on Medtronic (MDT) to $104 from $102 and keeps an Overweight rating on the shares. The firm notes the company reported a strong…
Medtronic price target raised to $110 from $95 at BofA
BofA raised the firm’s price target on Medtronic (MDT) to $110 from $95 and keeps a Buy rating on the shares. Almost every business unit ex-CAS has a growth driver…
Medtronic price target raised to $95 from $80 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Medtronic (MDT) to $95 from $80 and keeps a Hold rating on the shares. Medtronic “delivered on its promise” for…
Medtronic price target raised to $100 from $91 at Baird
Baird raised the firm’s price target on Medtronic (MDT) to $100 from $91 and keeps a Neutral rating on the shares. The firm updated its model following results which showed…
6 Dividend Aristocrats to Play Right Now
Medtronic, McCormick and T. Rowe Price are among the stocks that have outperformed the S&P 500 over the past three months—and have dividend yields of at least 3%.
Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses
Geoff Martha, Medtronic CEO, joins 'Squawk on the Street' to discuss shares rising Tuesday after the company announced a $700 million investment in Cornerstone Robotics, a robotic surgical company.
Medtronic price target raised to $100 from $91 at BTIG
BTIG raised the firm’s price target on Medtronic (MDT) to $100 from $91 and keeps a Buy rating on the shares following the company’s Q1 results. The news regarding Medtronic’s…
Midday Fly By: Medtronic reports Q1 beat, Ternus takes over as Apple CEO
The major averages were broadly lower to start the month of September as inflation concerns and rising oil prices lifted bond yields in the U.S. and elsewhere. Worries continue to…
Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech & Robotics
Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms.
Medtronic Earnings Call Transcript: Q1 2027
Q1 FY27 saw 13.7% organic revenue growth to $9.8B and adjusted EPS of $1.45, with broad-based strength across major business units and significant contributions from CAS, Altaviva, and robotics. FY27 guidance was raised for both revenue and EPS, supported by strong execution and innovation.
Medtronic Earnings release: Q1 2027
Medtronic released its Q1 2027 earnings on September 1, 2026, summarizing the period's financial results.
Medtronic Slides: Q1 2027
Medtronic has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on September 1, 2026.
Medtronic Quarterly report: Q1 2027
Medtronic has published its Q1 2027 quarterly earnings report on September 1, 2026.
Medtronic Stock Rises on Better-Than-Expected Earnings and $700 Million Investment in a Robot Surgeon
Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.
Medtronic reports Q1 non-GAAP EPS $1.45, consensus $1.39
Reports Q1 revenue $9.8B, consensus $9.54B. “We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly,…